Ex Vivo Normothermic Perfusion in Kidney Transplantation.

Официальное название

Multicenter, Prospective and Open-label Clinical Trial to Evaluate the Viability, Performance and Safety of ex Vivo Normothermic Perfusion in Kidney Transplantation From DCD and DBD Donors.

Обзор

A multicenter, prospective and open-label clinical investigation to evaluate the viability, performance and safety of ex vivo normothermic perfusion in kidney transplantation from DCD and DBD donors.

Подробное описание

The Ark Kidney is a medical device for ex vivo normothermic perfusion intended to create the conditions that allow kidneys to be resuscitated and / or preserved prior to transplantation. It consists of a permanent unit, which is retained after each perfusion, and a disposable circuit called the ARK Kidney Kidney Disposable Set (KDS), which must be replaced after perfusion to ensure sterile conditions.

It is a portable organ perfusion system designed to preserve a kidney by continuous perfusion of the donated organ with warm oxygenated perfusate supplemented with erythrocytes from the blood bank. The perfusion solution circulates continuously through the vascular network of the organ in a closed circuit. During perfusion, the system can monitor organ perfusion parameters, as well as the conditions of the perfusion solutions and the volume of urine generated during the perfusion.

The primary objective of the clinical study is to assess the viability, performance and safety of ex vivo normothermic perfusion with the Ark Kidney in kidney transplantation from DCD and DBD donors.

Вмешательства

• Устройство Ex vivo normothermic perfusion
  Ex vivo normothermic perfusion (EVNP) of the renal graft with the Ark Kidney System
• Устройство Cold preservation
  Static cold storage (SCS) or hypothermic machine perfusion (HMP) of the renal graft

Первичные конечные точки

• Safety of EVNP in kidney transplantation from DCD and DBD donors as evaluated by assessment of adverse events [Срок оценки: 1 year]

Вторичные конечные точки (12)

• Delayed graft function (DGF) [Срок оценки: 1 week]
• Duration (in days) of delayed graft function (DGF) [Срок оценки: 1 month]
• Proportion of patients with functional delayed graft function (fDGF) [Срок оценки: 1 week]
• Primary non-function (PNF) [Срок оценки: 1 week]
• Graft renal function (1 day) [Срок оценки: 1 day]
• Graft renal function (3 days) [Срок оценки: 3 days]
• Graft renal function (5 days) [Срок оценки: 5 days]
• Graft renal function (7 days) [Срок оценки: 7 days]
• Graft renal function (30 days) [Срок оценки: 30 days]
• Graft renal function (90 days) [Срок оценки: 90 days]
• Patient survival [Срок оценки: 1 year]
• Graft survival [Срок оценки: 1 year]

Критерии участия

Критерии включения

• Patients aged 18 years and older
• Patients undergoing renal replacement therapy by means of dialysis and included in the waiting list for renal transplantation in their respective site.
• Candidates to receive a first or second renal transplant from (i) a Maastricht type III (Maastricht classification) controlled DCD donor or (ii) a DBD donor aged 70 years or older.
• Patients that have given informed consent in written form before their inclusion in the study. In case of compromised mental capacity, the approval and signature of a legal guardian will be required.
• Patients compliant with the requirements of the study and without impediments to follow the instructions throughout the 1-year duration of the study.
• Patients that meet the acceptance criteria for kidney transplant recipients established in the clinical site in agreement with usual clinical practice.

Критерии исключения

• Two or more previous kidney transplantations
• Dual kidney transplantation or multivisceral transplantation (e.g. a pancreas-kidney transplantation)
• Recipients of an organ with any of the following characteristics:

• Expected cold ischemia time before EVNP > 20 hours
• Organ from hepatitis B surface antigen-positive or hepatitis C viremic donor
• Organ with multiple arteries
• Recipients with body mass index (BMI) > 40 kg/m2
• Diagnosis of focal segmental glomerulosclerosis (FSGS) or membranoproliferative glomerulonephritis with high recurrence risk after transplantation in the eyes of the investigator.
• Diagnosis of atypical hemolytic-uremic syndrome or thrombotic microangiopathy at the moment of inclusion
• Diagnosis of antiphospholipid syndrome at the moment of inclusion
• Panel-reactive antibodies (PRA) score > 50%
• Known allergies to any of the components of the perfusate
• Preexisting vascular disease that represents an extraordinary technical difficulty for the transplantation in the opinion of the investigator
• Presence of clinically relevant donor-specific anti-HLA antibodies
• ABO incompatibility
• History of alcohol or drug abuse in the last two years
• Use of normothermic regional perfusion during the organ harvesting process
• Participation of the patient in another study or clinical trial.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Нерандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Испания · 1 центр

• Miguel Servet University Hospital — Zaragoza

Идентификаторы

NCT: NCT05175885 · KidneyARK

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗